Don't Get Ahead of Yourself<br />By Rev Shark<br />RealMoney.com Contributor<br />7/1/2010 8:39 AM EDT <br /><br />Because things are the way they are, things will not stay the way they are. <br />-- Bertolt Brecht<br /><br />The most remarkable thing about this market recently is how it has continued to trend straight down without any sort of oversold bounce at all. We didn't even see any signs of end-of-the-quarter window dressing, which usually gives us at least a short-lived boost. <br /><br />So will the start of a new month and the positive seasonality in front of the 4th of July weekend kick in and finally give us some sort of relief bounce? <br /><br />One of the problems lately is that there have been too many traders trying to anticipate a bounce. They take some long positions only to rush to the exits when strength fails to develop, adding to the selling pressure. That behavior has caused a number of weak finishes lately. <br /><br />What is amazing about this action is how it is almost a complete inverse to the rally we had just a few months ago in March and April. Back then, traders kept trying to anticipate a top as the market plodded higher just about every day on low volume. The folks who kept trying to catch the turn ended up being short-squeeze fodder that just kept us going higher. <br /><br />It is always tough to catch a market turn, but it nearly irresistible to many market players. They don't want to continue to ride a trend because they are afraid that it is too extended, so they look to catch a countertrend move at just the right time. <br /><br />Catching market turns is such a hard thing to do, because the market just isn't a very rational beast. It might seem reasonable to us that we have a bounce after going down seven or eight days in a row, but our idea of what is reasonable just doesn't apply to the market. We all know we will have a good bounce at some point, but trying to time it with any degree of precision is a nearly impossible task. <br /><br />In addition to the persistent downtrend, another remarkable phenomenon lately has been how poorly some key blue-chip names have been acting. Stocks that many would view as "conservative" and "safe" like Wal-Mart (WMT) , Microsoft (MSFT) , Cisco (CSCO) , Home Depot (HD) , ExxonMobil (XOM) , Intel (INTC) and GE (GE) have dropped straight down during this market meltdown. There has been absolutely no buying interest in these names, which are often regarded as safe havens when the market is struggling. <br /><br />My theory to explain this relative weakness in the big-caps is that it is a function of a sudden reduction in liquidity. When there is a lot of cash out there and funds need to park it someplace, they go to those big names. With the bailouts and stimulus funds now pretty much digested, there just isn't the same amount of cash out there and the bids are disappearing. <br /><br />My approach to the market at this juncture remains the same as it has been since we topped out in early May. Respect the fact that we are in a downtrend above all else, and don't be too quick to anticipate a market turn. Yes, we will have some bounces and if you are quick and nimble you should trade them, but don't trust the upside to last. When the market turns back up, there will be plenty of time to build longer-term positions. You don't need to be in at the exact low to make good money, but you do need to avoid big losses if you want to produce exceptional returns. <br /><br />We have mild action to start the day. Asian and European stocks were all red as concerns continue over a slowdown in China and Spain struggles after Moody's placed their debt on watch for a downgrade. <br />-----------------------------------<br />Briefing.com vahendusel:<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: AFOP +11.5% (thinly traded), SWHC +7.6% (also upgraded to Buy from Neutral at Merriman), CBK +5.0%, SCHN +2.0%, XRTX +1.7%. <br /><br />Select financial related names ticking higher: STD +2.6%, CS +2.2%, NBG +1.8%, ING +1.8%, LYG +1.6%, AIB +0.9%. <br /><br />Select metals/mining stocks trading higher: MT +2.7%, RTP +2.1%, BBL +1.1%. <br /><br />Other news: GYRO +43.1% (Court of claims issues favorable opinion in condemnation litigation), ARNA +30.3% (announces that Eisai will market lorcaserin for obesity and weight management in the U.S. following FDA approval under the terms of a marketing and supply agreement), CTIC +13.5% (announces that it has deposited $39.3 mln in cash, which is an amount sufficient to pay and discharge the entire amount due on the Notes), ISLE +10.7% (postpones 9.0 mln common share offering due to recent market conditions), TSLA +4.9% (recent IPO seeing early strength), CYCC +4.7% (announces FDA orphan drug designation for Sapacitabine in both AML and MDS), QGEN +2.2% (still checking), YHOO +1.2% (announces $3 bln stock buyback program in an 8-K).<br /><br />Analyst comments: AVNR +10.9% (initiated with a Buy at Jefferies; $10 tgt), NOK +3.8% (upgraded to Neutral from Reduce at WestLB), THC +2.3% (upgraded to Outperform from Market Perform at Wells Fargo), LULU +2.1% (upgraded to Outperform from Neutral at B), DELL +1.6% (upgraded to Buy from Neutral at UBS ), SI +1.5% (upgraded to Add from Neutral at WestLB).<br /><br />Allapoole avanevad:<br /><br />In reaction to disappointing earnings/guidance: TASR -11.3%, APOL -2.0%. <br /><br />Select gold related stocks trading lower: AU -2.2%, HMY -1.8%, GLD -0.4%. <br /><br />Other news: DNDN -12.8% (CMS received informal inquiries for NCD for autologous cellular immunotherapy treatment of prostate cancer), SNSS -12.8% (sold $28.5 million of common stock at a price of $0.275 per share), ITUB -9.8% (light volume; trading ex dividend), AMED -9.0% (receives notice of SEC investigation; also downgraded to Hold from Buy at BB&T), NCT -7.1% (elected not to pay a common stock or preferred stock dividend), EXEL -4.0% (announces appointment of new CEO), SNTS -1.2% (light volume; announces launch of prescription ZEGERID authorized generic and company restructuring). <br /><br />Analyst comments: STP -1.9% (downgraded to Underperform from Market Perform at Raymond James).